Singularity Future Technology Announces $30M Private Placement and Warrant Amendment

What Happened

• Singularity Future Technology Ltd. (SGLY) announced a private placement of units to 18 investors under a Securities Purchase Agreement (SPA), generating approximately $30 million in gross proceeds. The Company sold an aggregate 32,188,841 units (equal to 2,299,212 units on a post-1:14 reverse-split basis); each unit consists of one share of common stock and three warrants.
• On August 12, 2026 the Company and the investors agreed to amend the SPA to replace the original warrants with Amended and Restated Warrants exercisable to purchase one share at an exercise price of $0.001. The issuance of those amended warrants is subject to shareholder approval. Also on August 12, 2026 the Company issued 2,299,212 shares of common stock to the investors in reliance on Regulation S (non-U.S. persons). The amended warrants have not been issued and will not be issued unless shareholders approve.

Key Details

• Units sold: 32,188,841 units (2,299,212 post-1:14-reverse-split basis).
• Proceeds: approximately $30 million gross from the Offering.
• Warrants: originally exercisable at $1.165 (pre-split) / $16.310 (post-split); amendment sets exercise price to $0.001 for each Amended and Restated Warrant.
• Issuance: 2,299,212 shares issued on August 12, 2026 in reliance on Regulation S; amended warrants require shareholder approval before issuance.

Why It Matters

• Financing: The transaction provides the company with substantial near-term capital (about $30M), which can support operations or strategic plans.
• Potential dilution: If shareholders approve the amended warrants at a $0.001 exercise price, holders could acquire a significant number of shares at a nominal price, which would dilute existing shareholders’ ownership. The amended warrants are not effective until shareholder approval is obtained.
• Regulatory/market effects: The initial share issuance was to non-U.S. persons under Regulation S, and the amended warrants are conditioned on corporate approval—investors should watch for the company’s proxy/meeting disclosure and any changes to outstanding share counts.